[go: up one dir, main page]

CN115884970A - 芳基甲酰胺类化合物及其制备方法和医药用途 - Google Patents

芳基甲酰胺类化合物及其制备方法和医药用途 Download PDF

Info

Publication number
CN115884970A
CN115884970A CN202180049562.3A CN202180049562A CN115884970A CN 115884970 A CN115884970 A CN 115884970A CN 202180049562 A CN202180049562 A CN 202180049562A CN 115884970 A CN115884970 A CN 115884970A
Authority
CN
China
Prior art keywords
preparation
medical application
application
formamide compounds
aryl formamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049562.3A
Other languages
English (en)
Inventor
殷惠军
闫旭
宗利斌
刘国标
张守良
陈彬
路嘉伟
王卓
栗睿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN115884970A publication Critical patent/CN115884970A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一类芳基甲酰胺类化合物及其制备方法和医药用途。特别地，涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为P2X3受体拮抗剂的用途，和用于治疗和/或预防与P2X3受体活性相关的疾病例如慢性咳嗽、疼痛、子宫内膜异位、膀胱过度活动症等的用途。其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180049562.3A 2020-09-24 2021-09-24 芳基甲酰胺类化合物及其制备方法和医药用途 Pending CN115884970A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020110122161 2020-09-24
CN202011012216 2020-09-24
PCT/CN2021/120150 WO2022063205A1 (zh) 2020-09-24 2021-09-24 芳基甲酰胺类化合物及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CN115884970A true CN115884970A (zh) 2023-03-31

Family

ID=80844951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049562.3A Pending CN115884970A (zh) 2020-09-24 2021-09-24 芳基甲酰胺类化合物及其制备方法和医药用途

Country Status (2)

Country Link
CN (1) CN115884970A (zh)
WO (1) WO2022063205A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037974A1 (en) * 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3
CN101528717A (zh) * 2006-11-09 2009-09-09 弗·哈夫曼-拉罗切有限公司 噻唑和唑-取代的芳基酰胺类化合物
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CN102803245A (zh) * 2009-06-22 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和/或p2x2/3拮抗剂的新的吲哚、吲唑和苯并咪唑芳基酰胺类
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
CN114728946A (zh) * 2019-09-25 2022-07-08 辉瑞公司 Sting (干扰素基因刺激剂)的多杂环调节剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238647B2 (en) * 2009-03-23 2016-01-19 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
HK1226718A1 (zh) * 2013-12-16 2017-10-06 Asana Biosciences, Llc P2x3及/或p2x2/3化合物及方法
WO2020239951A1 (en) * 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
EP3757103A1 (en) * 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037974A1 (en) * 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3
CN101528717A (zh) * 2006-11-09 2009-09-09 弗·哈夫曼-拉罗切有限公司 噻唑和唑-取代的芳基酰胺类化合物
WO2010111060A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CN102803245A (zh) * 2009-06-22 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和/或p2x2/3拮抗剂的新的吲哚、吲唑和苯并咪唑芳基酰胺类
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
CN114728946A (zh) * 2019-09-25 2022-07-08 辉瑞公司 Sting (干扰素基因刺激剂)的多杂环调节剂

Also Published As

Publication number Publication date
WO2022063205A8 (zh) 2023-03-30
WO2022063205A1 (zh) 2022-03-31

Similar Documents

Publication Publication Date Title
CN115698022A (zh) 五元杂芳并咪唑类化合物及其应用
CN114616232A (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
CN115279760A (zh) 新型hpk1抑制剂及其制备方法和应用
CN114728974A (zh) 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN116113632A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN114829364A (zh) 抑制并诱导降解egfr激酶的化合物
CN114746413A (zh) 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
CN114423760A (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
CN111295372A (zh) 硝羟喹啉前药及其用途
CN116134029A (zh) 氧代氮环类衍生物调节剂、其制备方法和应用
CN114901656A (zh) 羟肟酸酯化合物、其制备方法及其应用
CN111770754A (zh) 一种多环类衍生物调节剂、其制备方法和应用
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
CN115515949A (zh) 新型氨基嘧啶类egfr抑制剂
CN110461841A (zh) 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
CN114555600A (zh) 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
CN114829365A (zh) 作为erk抑制剂的噻唑并内酰胺类化合物及其应用
CN115038707A (zh) 氮杂卓类稠环化合物及其医药用途
CN111699174A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN112867717A (zh) 用作激酶抑制剂的化合物及其应用
CN114466846A (zh) 作为prmt5抑制剂的取代三环类化合物及其应用
CN115135649A (zh) 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
CN115667246A (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination